Makary, RFK Jr. Signal Mifepristone REMS Changes, But No Removal

By Cara Smith / September 24, 2025 at 1:52 PM

Despite GOP state attorneys general requests that HHS should consider removing mifepristone from the market, HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary’s response letter indicates they are only considering modifying the Risk Evaluation and Mitigation Strategy (REMS) requirements for the abortion drug.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Makary, RFK Jr. Signal Mifepristone REMS Changes, But No Removal

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.